【摘要】：在經(jīng)濟形勢日益復雜多變的背景下，生物醫(yī)藥正成為繼新能源之后又一個增長最為迅速的高成長性行業(yè)之一。21世紀以來，生物技術(shù)與信息技術(shù)、納米技術(shù)、新材料等其他高技術(shù)相互結(jié)合，正在形成以基因技術(shù)為主要核心的生物醫(yī)藥技術(shù)產(chǎn)業(yè)鏈，這就為生物醫(yī)藥的高速良性發(fā)展提供了良好的契機。如今，世界上許多國家都不約而同的將生物醫(yī)藥技術(shù)作為21世紀科技發(fā)展的關(guān)鍵技術(shù)，我國也一直將生物醫(yī)藥作為生物技術(shù)研究開發(fā)的重點。經(jīng)過幾十年的發(fā)展，我國的生物醫(yī)藥正擺脫過去跟蹤模仿、項目攻堅以及單一技術(shù)突破的老路，逐漸向自主研發(fā)、產(chǎn)業(yè)集群化和全面協(xié)調(diào)的方向發(fā)展。不可否認，我國的生物醫(yī)藥在“先天條件不足”的情況下依然取得了不俗的表現(xiàn)。但是，在成績的背后，各種問題日益凸顯，其中，對投資風險的認識不足導致的投資失敗值得關(guān)注。然而，盡管目前對投資風險和生物醫(yī)藥其他方面的研究很多，但將兩者結(jié)合起來研究的卻很少，缺乏實用性及可操作性，難以對實踐發(fā)揮有效的引導作用。因此，加強對生物醫(yī)藥行業(yè)投資風險的研究具有很強的現(xiàn)實意義和必要性。 本文以生物醫(yī)藥行業(yè)中存在的投資風險為研究對象。在研究方法上不僅采用了傳統(tǒng)的規(guī)范研究，同時引入了實證研究的方法。結(jié)合國內(nèi)外相關(guān)研究，為了更好地評估生物醫(yī)藥的投資風險，筆者以投資風險的來源為依據(jù)建立風險評估指標體系，以反映投資風險的影響因素。在指標權(quán)重的賦予方式上則采用層次分析法進行賦值，最后運用模糊綜合分析法得到生物醫(yī)藥行業(yè)投資風險評估的結(jié)果。同時，本文以生物芯片、干細胞與再生醫(yī)學、疫苗與抗體工程和納米醫(yī)藥為例進行實證檢驗，運用該評估方法衡量了我國生物醫(yī)藥行業(yè)的投資風險水平。研究結(jié)果表明，投資生物芯片的風險水平為高風險，投資需謹慎；干細胞與再生醫(yī)學的投資風險水平為中等風險，可以進行適度投資；疫苗與抗體工程和納米醫(yī)藥的投資風險都為較高風險。相比前人的研究成果而言，本文在構(gòu)建生物醫(yī)藥投資風險指標的基礎(chǔ)上創(chuàng)建了評估生物醫(yī)藥行業(yè)投資風險的研究體系，該體系有利于對生物醫(yī)藥行業(yè)的投資風險進行初步判定，并為實際投資作鋪墊，也可為政府相關(guān)部門制定合理政策、引導生物醫(yī)藥行業(yè)健康有序的良性發(fā)展提供理論依據(jù)。
[Abstract]:In the context of the increasingly complex and changeable economic situation, biomedicine is becoming one of the fastest growing industries after new energy. Since the 21st century, biotechnology and information technology, nanotechnology, The combination of other high technologies such as new materials is forming an industrial chain of biomedical technology with gene technology as the main core which provides a good opportunity for the rapid and benign development of biomedicine. Nowadays, many countries in the world regard biomedical technology as the key technology of the development of science and technology in the 21st century, and our country has always regarded biomedicine as the key point of biotechnology research and development. After decades of development, biomedicine in our country is getting rid of the old way of track imitation, project attacking and single technology breakthrough, and gradually developing to independent R & D, industrial cluster and overall coordination. Undeniably, China's biomedicine has made a good performance under the condition of "insufficient congenital conditions". However, behind the achievements, various problems become increasingly prominent, among which, the investment failure caused by insufficient understanding of investment risk is worthy of attention. However, although there is a lot of research on investment risk and other aspects of biomedicine at present, the combination of the two is seldom studied, lacking practicability and maneuverability, so it is difficult to play an effective guiding role in practice. Therefore, it is of great practical significance and necessity to strengthen the research on investment risk of biomedical industry. This paper takes the investment risk in the biomedical industry as the research object. The research method not only adopts the traditional normative research, but also introduces the empirical research method. In order to better evaluate the investment risk of biomedicine, the author establishes a risk assessment index system based on the source of investment risk to reflect the influencing factors of investment risk. On the way of giving index weight, AHP is used to assign value. Finally, fuzzy comprehensive analysis is used to get the result of investment risk assessment in biomedical industry. At the same time, this paper takes biochip, stem cell and regenerative medicine, vaccine and antibody engineering and nano-medicine as examples to test the investment risk level of biomedical industry in China. The results show that the investment risk level of biochip is high, and the investment level of stem cell and regenerative medicine should be cautious, the investment risk level of stem cell and regenerative medicine is medium risk, and the investment level of stem cell and regenerative medicine can be moderately invested. The investment risk of vaccine and antibody engineering and nano-medicine are both high risk. Compared with the previous research results, this paper establishes a research system to evaluate the investment risk of biomedical industry on the basis of constructing the biomedical investment risk index, which is conducive to the preliminary determination of the investment risk in the biomedical industry. It can also provide theoretical basis for the relevant government departments to formulate reasonable policies and guide the healthy and orderly development of the biomedical industry.
【學位授予單位】：陜西科技大學
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：F275;F426.72

【參考文獻】

相關(guān)期刊論文 前10條

1 李玉彬;錢曉璐;;生物制藥產(chǎn)業(yè)發(fā)展現(xiàn)狀與趨勢[J];現(xiàn)代農(nóng)業(yè)科技;2010年15期

2 姚宇;侯建明;王欣;;風險投資項目技術(shù)風險管理研究[J];工業(yè)技術(shù)經(jīng)濟;2006年09期

3 徐國勝;陳飛虎;;我國生物醫(yī)藥產(chǎn)業(yè)發(fā)展現(xiàn)狀與策略[J];實用肝臟病雜志;2012年05期

4 王志華;;中國生物醫(yī)藥產(chǎn)業(yè)自主創(chuàng)新的維度分析[J];合肥工業(yè)大學學報(社會科學版);2010年01期

5 李田,孫平;淺析生物醫(yī)藥行業(yè)風險投資[J];科學與管理;2004年03期

6 陸怡;江洪波;;全球生物醫(yī)藥產(chǎn)業(yè)現(xiàn)狀與發(fā)展趨勢[J];科學;2012年05期

7 李建綱;我國生物醫(yī)藥產(chǎn)業(yè)發(fā)展中存在的問題與對策[J];醫(yī)藥世界;2005年01期

8 趙寧;;安泰康:中國生物醫(yī)藥業(yè)發(fā)展的引擎[J];中國高新技術(shù)企業(yè);2010年11期

9 范頌華;;研發(fā)型生物醫(yī)藥企業(yè)風險投資的價值評價體系研究[J];中國高新技術(shù)企業(yè);2011年01期

10 宿凌;;我國生物醫(yī)藥發(fā)展模式研究[J];中國藥房;2006年02期

相關(guān)碩士學位論文 前7條

1 孔雪;風險投資的評價體系研究[D];大連交通大學;2010年

2 朱燕婷;新能源產(chǎn)業(yè)投資風險分析與評估體系的構(gòu)建[D];浙江大學;2011年

3 王偉杰;生物醫(yī)藥產(chǎn)業(yè)園試產(chǎn)項目管理研究[D];天津大學;2010年

4 葉碧波;中國生物醫(yī)藥產(chǎn)業(yè)創(chuàng)業(yè)投資的風險研究[D];天津大學;2010年

5 李代紅;風險投資在生物技術(shù)產(chǎn)業(yè)的投資風險的研究[D];重慶大學;2005年

6 王曉玲;風險投資項目風險控制研究[D];西安科技大學;2006年

7 彭水梅;生物技術(shù)風險投資項目評估模型研究[D];湖南科技大學;2010年

，

本文編號：2282174